Topic: joint venture

Bayer, CRISPR Therapeutics JV to start at Kendall Square location

A biotech borne out of a JV between Bayer’s new research deals arm and CRISPR Therapeutics will start operations at life sciences hub Kendall Square in Cambridge, MA, next year as looks to get to work on a number of disease areas using the new CRISPR-Cas9 cutting-edge tech.